Testing Risvutatug Rezetecan for Advanced Bone and Soft Tissue Sarcomas
Treatments studied
Part of Cancer clinical trials.
This study tests a new cancer drug called risvutatug rezetecan for people with advanced sarcomas (bone or soft tissue cancers) that have stopped responding to prior treatments. The drug works by delivering a cancer-killing agent directly to tumor cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 12 years old
- You have a confirmed diagnosis of advanced or metastatic osteosarcoma (bone cancer) or soft tissue sarcoma that has progressed despite at least one prior treatment
- Your cancer has shown clear progression on imaging scans within the last treatment cycle
- You are in good overall health with minimal activity limitations (ECOG 0–1 or equivalent performance score)
- Your organ function (liver, kidney, heart, blood cells) is adequate to tolerate the study drug
- You have not previously received a similar drug type called antibody-drug conjugates (ADC) with a TOPO1-inhibitor payload
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a precision medicine approach by giving targeted therapy before surgery for high-risk soft tissue sarcoma. The goal is to see if matching treatment to your tumor's type can improve outcomes.
This trial tests retifanlimab (an immunotherapy that helps your immune system recognize cancer) combined with gemcitabine and docetaxel chemotherapy. It’s for people with advanced soft tissue sarcoma that can’t be safely removed with surgery, aiming to shrink tumors and improve outcomes.
This trial tests a combination of a PARP inhibitor drug, targeted radiation (SBRT), and immunotherapy for people with advanced sarcoma that has spread. It aims to see if this triple therapy can shrink tumors or slow the disease.
This trial tests a new drug called HS-20093 combined with other treatments for people with advanced bone or soft tissue sarcoma. It aims to find safe and effective combinations for those who haven't responded to standard treatments.
This study tests a new drug (GSK5764227) for people whose extensive-stage small cell lung cancer has gotten worse after platinum chemotherapy combined with immunotherapy. The goal is to see if this targeted treatment can help shrink tumors and control the cancer.
This study tests whether giving radiation, chemotherapy, and immunotherapy together can control high-risk soft tissue sarcoma that is hard to remove or may come back after surgery. It may help by attacking cancer in different ways, including boosting the immune system.
Hear when a new Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.